Drug Trial Radar · NCT03187288
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
May 25, 2018
Primary completion
Jun 30, 2021
Study completion Jun 30, 2021
Sponsor
- Lead sponsor
- University Health Network, TorontoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1 study of investigational drug CFI-400945 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome. The purpose of this phase 1 study is to see how safe and tolerable the study drug is and to determine the best dose (maximum tolerated dose or recommended phase 2 dose) that can be given in this patient population.
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Relapsed Cancer
- Refractory Cancer
Interventions
CFI-400945 FumarateDrug
CFI-400945 is an investigational drug that is being look at for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CFI-400945 is an oral (taken by mouth) drug that blocks Polo-like kinase 4 (PLK4) activity. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to contribute to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors from growing or shrink them.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of the frequency and severity of treatment-emergent adverse events in patientsTime frame: 5 years
- Highest tolerated dose of CFI-400945 fumarateTime frame: 5 years
- Recommended phase 2 dose of CFI-400945 fumarateTime frame: 5 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Juravinski Hospital and Cancer Centre
Hamilton, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.